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Summary 
 
Introduction: The present paper deals with the issue of the increasing usage of corporation mergers and 
acquisitions strategies within pharmaceutical industry environment. The aim is to identify the triggers of 
such business phenomenon and the immediate impact on the financial outcome of two powerful 
biopharmaceutical corporations: Pfizer and GlaxoSmithKline, which have been sampled due to their 
successful approach of the tactics in question. 
Materials and Methods: In order to create an overview of the development steps through mergers and 
acquisitions, the historical data of the two corporations has been consulted, from their official websites. The 
most relevant events were then associated with adequate information from the financial reports and 
statements of the two corporations indulged by web-based financial data providers. 
Results and Discussions: In the past few decades Pfizer and GlaxoSmithKline have purchased or merged 
with various companies in order to monopolize new markets, diversify products and services portfolios, 
survive and surpass competitors. The consequences proved to be positive although this approach implies 
certain capital availability.    
Conclusions: Results reveal the fact that, as far as the two sampled companies are concerned, acquisitions 
and mergers are reactions at the pressure of the highly competitive environment. Moreover, the continuous 
diversification of the market’s needs is also a consistent motive. However, the prevalence and the eminence 
of mergers and acquisition strategies are conditioned by the tender offer, the announcer’s caliber, research 
and development status and further other factors determined by the internal and external actors of the market.  
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1. Introduction 
The Pharmaceutical Industry is nowadays one of the most expansive and profitable industries in the 
world, with a highly important impact as it targets the quality of life. This type of healthcare industry started 
as a local drugstore in the 18
th
 century when, the manufacturing and selling of drugs to cure diseases has 
shown, for the first time, its profit potential. As a result, it has grown, over the last centuries, into large 
pharmaceutical companies, especially when new and essential drugs have started to be discovered, such as 
insulin or penicillin whose accessibility to the mass population was vital.  Moreover, it is an environment 
which nowadays is continuously undergoing dramatic changes. Everyday a new competitor arises, a new 
product or concept is being launched, a new marketing strategy is being developed. In addition, it is by law 
of nature for the strongest to survive, especially when there are so many constrains that ought to be taken 
into consideration such as the internal actors of the market structure (demand, supply, retailers, prescribers or 
opinion leaders) and the external environment (regulations, technology, economy, socio-cultural aspects). 
The marketing concept that holds the key to achieving organizational goals consists of the company being 
more effective than competitors in creating, delivering, and communicating superior customer value to its 
chosen target markets [1]. Furthermore, gaining competitive advantage implies internal development 
(organic growth), external development (external growth through mergers, acquisitions of titles, companies 
etc.) and contractual development [2]. In the pharmaceutical environment, mergers and acquisitions have 
proved to be very popular as they have been used both for creating strong companies and for conquering new 
markets, as far as healthcare services and geographical expansions are concerned. A couple of solid 
examples would be the rise and development of Pfizer and GlaxoSmithKline (GSK), two of the most 
powerful multinational pharmaceutical companies in the world. Multinational corporations, as organizations 
with diversified activities, localized in multiple geographical aerials, wouldn’t be able to practice their 
strategies without having an adequate structure to the ultimate goal on an international level [3]. External 
development is an adequate measure in a competitive environment which imposes achieving certain 
dimensions or owning a minimum market share in order to remain present in an evolving and fluctuating 
market sector. It is also a comfortable way to engage in a diversification strategy [2]. ACQUISITION is a 
technique through which an enterprise acquires a sufficient number of shares in order to gain control of the 
emitting company. After the takeover proceedings, the companies are juridical independent however, the 
company in control together with the controlled one form a group. As concrete ways of acquisition 
materialization the following can be mentioned: tender offer (public offer of purchase – that can be 
diplomatic or hostile); exchange public offer (exchange of the owned titles by the targeted company with the 
titles of the company that launches the proposal); negotiation of a control centre (acquisition of a title 
package that assures control power); creeping tender (acquisition of a large number of shares from the 
secondary market and usually precedes the launch of a tender offer); proxy fight (gaining control over an 
enterprise by obtaining the majority of the titles in the Administration Council, not by holding the majority 
of shares). The share selling and buying actually implies the commercialization of an enterprise, partially or 
totally. As a result, acquisitions can be made through its titles – concentration of a sufficient volume of titles 
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is the most important mean of controlling a ranked company. The possibility of share acquisition creates 
amplification of the industrial structure mobility, redistribution of capitals between different economic 
activity sectors. MERGER is another technique that implies transfer of ownership and control of a company 
(usually when two firms have resources and abilities that brought together create a stronger competitive 
advantage). The most frequent used in the pharmaceutical sector are the fusions made through absorption 
(the controlled company is being dissolved) or through consolidation (both companies disappear and a new 
one is being founded) [2]. As far as the unit structure is concerned there can be distinguished: horizontal 
mergers (realized by competitive entities with the same product), vertical mergers (between commercial 
partners like client – provider), concentric mergers (between entities who do not have commercial 
relationships and do not sell the same product, but are complementary) and conglomerate mergers (between 
entities form different areas of activity, their ultimate goal being the diversification of activities with 
minimum risks) [2]. Considering all the above, the purpose of this article is to study the amplitude of merger 
and acquisition strategies, to particularly identify the motifs of their usage, what do these market 
phenomenon imply and which are the immediate consequences upon the biopharmaceutical business of two 
of the most profitable multinational enterprises in the Pharmaceutical Industry: Pfizer and GlaxoSmithKline.  
 
2. Material and Methods  
Two well established pharmaceutical and biotechnology corporations: Pfizer and GlaxoSmithKline 
have been sampled in order to have a wider perspective of the amplitude of mergers and acquisitions 
strategies from two marketing management style angles.  Their strategic steps were approached after 
consulting the historical data [4,5] of the two corporations provided by their official websites. Moreover, in 
order to assess the impact of this strategic approach, financial data regarding Pfizer[6] and GSK[7] have been 
collected from the corporate websites, “Institution of Mergers, Acquisitions and Alliances”[8], 
“BioSpace”[9], “Pharmexec"[10]. The last, being web-based providers of financial data regarding companies 
from around the world.  
 
3. Results and Discussions 
According to the “Institute of Mergers, Acquisitions and Alliances” (IMAA), this type of business 
development has confronted with a presumptuous evolution worldwide in the past two decades reaching 
transactions of billions of dollars.  In 2007 both the value and the frequency of mergers and acquisitions have 
reached the highest pick: 50.000 transactions of over 5.000 billion USD. Although, since 2007 the value of 
the transactions has decreased (an explainable consequence of the economical crisis occurrence) the number 
of such events has kept a high profile as illustrated in Fig.1. 
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Fig.1 Announced Mergers & Acquisitions Worldwide [8] 
 
Even though the energetic and communication sectors are the most active from this point of view, 
Pfizer and GSK, as representatives of the Healthcare Industry, have succeeded in being responsible of  two 
of the top 10 deals both at an European level(GSK placed 4
th
) and worldwide, making transactions of over 70 
billion dollars (Table I). 
Table I. Worldwide Transactions based on IMAA data [8] 
Rank Year Acquiror Target Transaction(bil.USD) 
1 1999 Vodafone AirTouch PLC Mannesmann AG 202.8 
2 2000 America Online Inc Time Warner 164.7 
3 2007 Shareholders Philip Morris Intl Inc 98.2107.6 
4 2007 RFS Holdings BV ABN-AMRO Holding NV 98.2 
5 1999 Pfizer Inc Warner-Lambert Co 89.2 
6 1998 Exxon Corp Mobil Corp 78.9 
7 2000 Glaxo Wellcome PLC SmithKline Beecham PLC 76.0 
8 2004 Royal Dutch Petroleum Co Shell Transport & Trading Co 74.6 
9 2006 AT&T Inc BellSouth Corp 72.7 
10 1998 Travelers Group Inc Citicorp 72.6 
 
As illustrated in Fig.2, Pfizer’s Warner-Lambert acquisition (two of the top pharmaceutical 
companies) in 1999 has certainly left an imprint on the Biotechnology and Pharmaceutical market and 
secured a top spot for Pfizer. 
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Fig.2 Announced Mergers & Acquisitions in Biotechnology & Pharmaceutical sector [8] 
 
However, this was not the first merger-acquisition phenomenon in Pfizer’s history. Since 1862 
Pfizer, founded by cousins Charles Pfizer and Charles Erhart in 1849, has experienced an accelerated organic 
development encouraged by the external market actors who provided favorable circumstances. With the 
occurrence of the Civil War, a consistent governmental demand for painkillers, preservatives, and 
disinfectants was advanced. Thus, the company was stimulated to expand their drug offer and also to tap into 
mass production with the commercialization of iodine, morphine, chloroform, camphor, but also with 
mercurials (used in the emerging field of photography) tartaric acid and cream of tartar (products vital to the 
food and chemical industries),  citric acid (also used by Coca-Cola™, Dr. Pepper™, and Pepsi-Cola™). We 
can observe the fact that even from de beginning Pfizer’s politics targeted, not only the healthcare 
environment but, also other emerging industries that could benefit from their products, thus inferring future 
absorption mergers. As a result, the incomes doubled and assured a successful development in the following 
decades as the company highly invested not only in the discovery and mass production of new drugs but also 
in the development of production technologies.  Penicillin (the "miracle drug") and oxytetracycline (first real 
defense against bacterial infection) proved to be a turning point in human history and in the history of Pfizer 
due to the fact that they actually assured international expansion. In addition, Pfizer created the International 
Divisions by sending specially trained pharmaceutical salesmen to promote Pfizer's first proprietary 
pharmaceutical products.  Between 1952 and 1953 Pfizer tries to reach other branches of the industry by 
opening animal health division. This was actually the first initiative of business expansion through a 
diplomatic tender offer acquisition that assured the activity diversification by purchasing SmithKline 
Beecham's animal health business. The acquisition of $1.45 billion in cash fallowed the tender offer made as 
a response to SmithKline Beecham's public selling offer (whose goal was to reduce the company’s debts).  
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This strategy made Pfizer a world leader in the development and production of pharmaceuticals for livestock 
and companion animals [4]. Even though this tactic seams to target different objective, the ultimate goal was 
still the assurance of human wellbeing. Animal healthcare improvement actually assured the quality and 
safety of meat based food products. Moreover, animal drug studies helped new drug developments or new 
pharmacological effects discovery. Another opportunistic approach was targeting the enhancing of pet’s life 
quality. Pet care became an emerging and promising business closely related to the pharmaceutical industry 
as veterinaries started to use Prozac for depressed dogs. This initiative triggered the investments in 
Companion Animals Healthcare division. As a result, by adopting an indirect approach of the same market 
target they succeed in gaining new clients, maintaining old ones and even creating new markets.  The 
affiliation of Warner-Lambert, announced in 1999 and completed by June 2000, was a hostile acquisition 
whose tender offer was triggered by Warner-Lambert’s merger intentions with another biopharmaceutical 
company, that threatened Lipitor(cholesterol-lowering statin)co-marketing agreements.  Pfizer realized a 
veritable transfer of power and control with an organic restructuration and patrimonial mutation that 
concretized in surpassing the imperatives of the economical growth. With Warner-Lambert, Pfizer gained 
full Lipitor ownership and diversified its product lines from Parke-Davis branded pharmaceuticals to 
Listerine mouthwash to Schick and Wilkinson Sword wet-shave products [4]. Thus, not only did Pfizer 
enlarged product portfolio but also extended market areal by absorbing Werner-Lambert’s personalized 
market. Another advantage was the actual reduction of the company’s costs with approximately $6 billion 
(as stated in the 2005 financial annual report). Even though Pfizer invested a large capital for the acquisition, 
the results did not fail to make the difference as in the next 6 years Pfizer’s income tripled, reaching total 
revenue of $51.3 billion in 2005. However, the net income of $8.1 billion was in fact 2% lower in 
comparison with the $11.4 billion, in 2004. The 2% decrease was the main consequence of the company 
continuous expansion based on the same acquisition-merger strategy. In 2005, $1.9 billion in cash were 
allocated for the acquisition of Vicuron Pharmaceuticals (a biopharmaceutical company specialized in 
discovery, development, manufacturing of new-generation drugs, especially anti-infectious ones) and $298 
billion in cash for Idun Pharmaceuticals (a biopharmaceutical company focused on the discovery and 
development of therapies to control apoptosis). These were the results of a long term research collaboration 
agreement between Pfizer and the two companies.  As far as Vicuron is concerned, Pfizer began by 
purchasing some of their products like Anidulafungine and Dalbavancin. The next step was the acquisition 
through negotiation of a control center - by purchasing the majority of shares of Vicuron’s common stock 
with $29.10 per share in cash adding up to approximately $1.9 billion. As stated in the 2006 financial report, 
this transaction builds on Pfizer’s extensive experience in anti-infectives and demonstrated commitment to 
strengthen and broaden its pharmaceutical business through strategic product acquisitions [6]. The 
penetration of the anti-infective market was a strategic move due to the fact that nowadays infectious 
diseases are extremely wide-spread and antibiotic resistance has become a concerning aspect that requires 
taking into consideration new drug designs and also proper patient counseling.  2006 is characterized by 
lower acquisition related expenses - $835 million for Powder Med Ltd., (specialized development and 
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manufacture of DNA-based vaccines for viral diseases and cancer) and Rinat Neuroscience Corp. 
(specialized in protein-based drugs for nervous system therapies). To the latter, a tender offer was made. In 
response, Rinat declared to be pleased that Pfizer, the largest pharmaceutical company and a leader in 
neuroscience, has recognized the potential of their programs to treat significant unmet medical needs [9]. The 
diplomatic takeover targeted enlargement of drug portfolio and insertion into new therapeutical markets with 
yet unexploited profit potential. More acquisition investments have been made in the next period: $283 
million for the affiliation of company specialized in anti-diabetics and new protein drugs (BioRexis) and a 
concentric merger with an animal health company (Embex). Furthermore, in 2008 Pfizer and Wyeth start the 
merger agreements that will result in a $68 billion absorption-consolidation merger transaction in 2009, the 
second most important investment after the $89.2 billion acquisition of Warner-Lambert in 2000. Regardless 
the fact that 2008 was an economically concerning moment for Pfizer due to multiple drug patent expiration 
including Lipitor (which assured a consistent 25% of the firm’s incomes, according to the financial reports), 
the company took the risk of expanding. Under the given circumstances, even though it was expected for 
Novartis, Sanofi, and GSK to all overtake the company by 2013, based on this deal, and if the other 
companies do not partake in Merger and Acquisition activities, Pfizer is to stay in the top spot in 2013 [10]. 
In addition, we can safely assume that for the first time the merger-acquisition strategy was not done with the 
direct purpose of organic development but with the intention of surviving and gaining advantage over 
competitors in the increasingly aggressive pharmaceutical environment. What makes a merger like this so 
attractive is the ability to maintain revenue levels and cut costs by eliminating redundancies [10]. According 
to the 2009 financial report the Wyeth merger was initiated through the acquisition method of accounting. As 
a result, a full inventory of the two companies was done before merging in order to register the real value of 
the assets and liabilities to be acquired. The consequence was an increase in the net income from $8.104 
million in 2008 to $10.009 million in 2011, as shown in table IV (based on 2011 annual financial report data) 
which also gives an overview of the total revenue and the acquisition investments from the past 5 years. 
 
Table IV. Financial evolution (in millions of USD) for the past 5 years [6] 
 2011 2010 2009 2008 2007 
Revenues 67,425 67,057 49,269 47,529 47,733 
Acquisition-related charges - 125 68 633 283 
Net income 10.009 8.257 8.635 8.104 8.144 
 
In the past 4 years Pfizer continued to expand its product portfolio with new vaccines, dietary 
supplements and lifestyle products, vitamins, generic drugs etc., by merging an acquiring biopharmaceutical 
companies specialized in drug research and manufacture. Pfizer also interceded to enhance the 
pharmaceutical industrial technology division by negotiating the control center of companies specialized in 
the desired technologies. In 2009 an interesting collaboration was initiated as both Pfizer and GSK merged 
their vaccine sector of their research division. As a result, ViiV Healthcare Limited, a new corporation was 
founded by means of cohesion-creation merger, with the exclusive and ultimate goal of research, 
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development and commercialization of human immunodeficiency virus (HIV) medicines. We are practically 
witnessing the fusion of two magnates of the pharmaceutical research industry whose financial resulted 
incomes will certainly intimidate the competitors. When it comes to GSK, its present market position is also 
the result of long series of acquisitions and mergers, however at a lower rate than Pfizer’s. The first merger 
was a cohesion-creation fusion through which SmithKline & Co. and Richards and Company (a French 
laboratory) sized to exist as independent entities in order to found SmithKline and Laboratories French in 
1891. The result was mainly diversification of product portfolio which was enriched with cosmetics 
(perfumes, liniments, tonics, hair oils, etc.) and an important palette of home remedies.  In the time being an 
important breach in the industry caught the attention of one of the founders, Mahlon Kline who saw a 
problem in filling orders and time delivering. Thus, SmithKline and Laboratories French was the first 
company to establish a policy through which they took the engagement of delivering all morning orders by 
late afternoon. It was an approach that will mark one of their future business strategies of development – 
Retail and Distribution.  However, the next century meant a research commitment for the company. As a 
consequence, most of the acquisitions were made with the intention of research development. The most 
important and innovative products, for that time, developed by their research division were: dried milk 
powder (which triggered the initiative of a baby product line development), poison ivy lotion, iron tablets 
and lozenges (products that formed “Blue Line”), laxatives, cold remedy powders (produced by Beecham), 
glycosides for heart failure treatment, a series of anti-bacterials, vaccines, etc. In order to improve their 
vaccine research division, Smith Kline and Laboratories French acquired, in 1963, Recherche et Industrie 
Thérapeutiques from Belgium.  In the next decade the company experienced a global expansion with the 
acquisition of some laboratories across Canada and USA, a skin care product specialized company. In 1988 
the company grows with 50% by acquiring one of its largest competitors, International Clinical Laboratories, 
for $400 million. The strategic purchase assured their market leadership. By 1989, the cohesion-creation 
merger with Beecham Inc. was finalized with the creation SmithKline Beecham (after a long collaboration 
based on product diversification: anti-invectives, vaccines, laxatives, cold powder etc.) with a stock value of 
₤107.3 billion. The ultimate goal was to gain competitive advantage by bringing together their resources and 
liabilities and also to cut costs (₤1.1 billion announced). Afterwards they continued investing in the purchase 
of new research laboratories but, they also began to acquire shares from Europharm, Romania, a company 
with a well established retail-distribution system on the regional market and also specialized in mass 
production of generics and OTCs. The acquisition started with the creeping tender (by 1998 they owned 43% 
of the firm) which was followed by the tender offer, thus full ownership was gained by 2003.As a result, 
SmithKline Beecham’s ultimate goal was not only to expand its product offer but also to conquer a new 
market with maximum avoidance of supplementary taxes, through ownership of local retail and distribution 
network, thus becoming the top leader of the Romanian pharmaceutical market. Meanwhile, in 2000 
SmithKline Beecham and Glaxo Wellcome sized their legal function and a patrimonial mutation of the two 
entities delivered GlaxoSmithKline (GSK). This was another cohesion-creation merger of $76.0 billion that 
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brought the new founded company: market expansion, enrichment of product offer, development of retail 
and distribution sector, lower chargers etc. 
 
4. Conclusions 
Both Pfizer and GSK have used merger-acquisition strategies mainly to expand their research and 
development department by targeting already developed companies with profitable products and services 
portfolios. Research and development evolution is incontestably the key for market supremacy and higher 
revenues as shown by the two companies’ market domination which is the actual result of their strategic 
mergers and purchases alongside with their intensive research projects.  As far as regional development is 
concerned, by comparison with Pfizer who always aimed at the top competitors on the market, GSK has 
focused mostly on smaller companies but more diversified as far as healthcare products and services are 
concerned. Furthermore, when entering in small regional pharmaceutical environments like the Baltic 
markets, GSK has concentrated its focus on small and solid multifunctional companies (owning generic lines 
of drugs, distribution facilities and retail) with potential of becoming top leaders in the targeted countries.  
Nevertheless, this type of business development approach has proved its efficiency by allowing 
biopharmaceutical players to raise the standards of their research and distribution divisions, to tap into 
emerging markets, to diversify product offers and healthcare services, to update their biotechnologies, to 
approach new therapeutical markets, to surpass intimidating competitors and survive in the aggressive, 
fluctuating and constrained environment of the pharmaceutical industry. All the enumerated benefits are 
finally reflected in costs, taxes and debts reductions which assure profits of millions of dollars. Thus can be 
explained the high frequency of merge-acquisition transactions as far as biotechnologies and pharmaceuticals 
are concerned.  
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